Form 4: Sage Therapeutics Chief Medical Officer Laura Gault Receives Stock Awards

Laura Gault, Chief Medical Officer of Sage Therapeutics, was granted 24,000 restricted stock units and also increased her holdings through the employee stock purchase plan.

Summary

• Laura Gault, the Chief Medical Officer of Sage Therapeutics, received 24,000 restricted stock units (RSUs) on January 16, 2025.
• These RSUs will vest in equal annual installments over four years, starting on January 16, 2026.
• Gault also increased her holdings by 597 shares through the company's Employee Stock Purchase Plan on December 31, 2024.
• Following these transactions, Gault's total beneficial ownership of Sage Therapeutics stock is 35,334 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally positive for the company's alignment of interests with its leadership. There are no negative implications.

Positives

• The grant of 24,000 RSUs to the Chief Medical Officer indicates the company's commitment to incentivizing key personnel.
• The vesting schedule of the RSUs encourages long-term alignment with the company's performance.
• Participation in the Employee Stock Purchase Plan demonstrates the executive's confidence in the company's future.

Future Outlook

The restricted stock units will vest over the next four years, starting January 16, 2026.

Industry Context

Stock grants and employee stock purchase plans are common practices in the biotechnology industry to attract, retain, and incentivize key executives.

Comparison to Industry Standards

• Stock-based compensation is a standard practice in the biotech industry, with companies like Biogen, Amgen, and Gilead Sciences also using RSUs and stock purchase plans.
• The vesting schedule of four years is typical for RSU grants, aligning with long-term performance goals.
• The amount of shares granted is within the range of what is expected for a Chief Medical Officer at a company of Sage Therapeutics' size and stage.

Stakeholder Impact

• The stock grants align the interests of the Chief Medical Officer with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Key Dates

Keywords

Sage Therapeutics, Laura Gault, Restricted Stock Units, RSU, Employee Stock Purchase Plan, Stock Ownership, Chief Medical Officer, Executive Compensation